Nanomedicine Combats Drug Resistance in Lung Cancer
Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy are currently available as treatment methods. However, drug resistance is a significant factor in the failure of...
Gespeichert in:
| Veröffentlicht in: | Advanced materials (Weinheim) 2024-01, Vol.36 (3), p.e2308977-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | e2308977 |
| container_title | Advanced materials (Weinheim) |
| container_volume | 36 |
| creator | Zheng, Xiuli Song, Xiaohai Zhu, Guonian Pan, Dayi Li, Haonan Hu, Jiankun Xiao, Kai Gong, Qiyong Gu, Zhongwei Luo, Kui Li, Weimin |
| description | Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy are currently available as treatment methods. However, drug resistance is a significant factor in the failure of lung cancer treatments. Novel therapeutics have been exploited to address complicated resistance mechanisms of lung cancer and the advancement of nanomedicine is extremely promising in terms of overcoming drug resistance. Nanomedicine equipped with multifunctional and tunable physiochemical properties in alignment with tumor genetic profiles can achieve precise, safe, and effective treatment while minimizing or eradicating drug resistance in cancer. Here, this work reviews the discovered resistance mechanisms for lung cancer chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy, and outlines novel strategies for the development of nanomedicine against drug resistance. This work focuses on engineering design, customized delivery, current challenges, and clinical translation of nanomedicine in the application of resistant lung cancer.
In this review, the discovered drug resistance mechanisms for lung cancer chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy are introduced. Recent advances of organic, inorganic, and bio‐derived nanomedicines for drug‐resistant lung cancer treatment are summarized. The engineering design, customized delivery, current challenges, and clinical translation of nanomedicine for lung cancer are discussed. |
| doi_str_mv | 10.1002/adma.202308977 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2890755376</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2890755376</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3737-e483669a8837e7804f57e1c8d019dcd38cd348eab84a3fa74e30795901f8f8ea3</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMotlavHmXBi5etk80mmRzL1i-oCqLnkO5my5b9qEkX6b83pbWCFw_DMMMzL8NDyCWFMQVIbk3RmHECCQNUUh6RIeUJjVNQ_JgMQTEeK5HigJx5vwQAJUCckgGTSiAKPiTsxbRdY4sqr1obZV0zN2sfTV2_iN6sr_zatLmNqjaa9e0iyraTOycnpam9vdj3Efm4v3vPHuPZ68NTNpnFOZNMxjZFJoQyiExaiZCWXFqaYwFUFXnBMFSK1swxNaw0MrUMpOIKaIll2LMRudnlrlz32Vu_1k3lc1vXprVd73WCCiTnTIqAXv9Bl13v2vCdThTlyLniNFDjHZW7zntnS71yVWPcRlPQW516q1MfdIaDq31sPw-SDviPvwCoHfBV1XbzT5yeTJ8nv-HfuHh-7w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2915855951</pqid></control><display><type>article</type><title>Nanomedicine Combats Drug Resistance in Lung Cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zheng, Xiuli ; Song, Xiaohai ; Zhu, Guonian ; Pan, Dayi ; Li, Haonan ; Hu, Jiankun ; Xiao, Kai ; Gong, Qiyong ; Gu, Zhongwei ; Luo, Kui ; Li, Weimin</creator><creatorcontrib>Zheng, Xiuli ; Song, Xiaohai ; Zhu, Guonian ; Pan, Dayi ; Li, Haonan ; Hu, Jiankun ; Xiao, Kai ; Gong, Qiyong ; Gu, Zhongwei ; Luo, Kui ; Li, Weimin</creatorcontrib><description>Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy are currently available as treatment methods. However, drug resistance is a significant factor in the failure of lung cancer treatments. Novel therapeutics have been exploited to address complicated resistance mechanisms of lung cancer and the advancement of nanomedicine is extremely promising in terms of overcoming drug resistance. Nanomedicine equipped with multifunctional and tunable physiochemical properties in alignment with tumor genetic profiles can achieve precise, safe, and effective treatment while minimizing or eradicating drug resistance in cancer. Here, this work reviews the discovered resistance mechanisms for lung cancer chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy, and outlines novel strategies for the development of nanomedicine against drug resistance. This work focuses on engineering design, customized delivery, current challenges, and clinical translation of nanomedicine in the application of resistant lung cancer.
In this review, the discovered drug resistance mechanisms for lung cancer chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy are introduced. Recent advances of organic, inorganic, and bio‐derived nanomedicines for drug‐resistant lung cancer treatment are summarized. The engineering design, customized delivery, current challenges, and clinical translation of nanomedicine for lung cancer are discussed.</description><identifier>ISSN: 0935-9648</identifier><identifier>EISSN: 1521-4095</identifier><identifier>DOI: 10.1002/adma.202308977</identifier><identifier>PMID: 37968865</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Antineoplastic Agents - pharmacology ; Cancer therapies ; Chemotherapy ; Design engineering ; Drug Delivery Systems ; Drug resistance ; Drug Resistance, Neoplasm ; Humans ; Immunotherapy ; Lung cancer ; Lung Neoplasms - drug therapy ; molecular targeted therapy ; Nanomedicine ; Neoplasms - drug therapy ; Physiochemistry ; Radiation therapy ; radiotherapy</subject><ispartof>Advanced materials (Weinheim), 2024-01, Vol.36 (3), p.e2308977-n/a</ispartof><rights>2023 Wiley‐VCH GmbH</rights><rights>2023 Wiley-VCH GmbH.</rights><rights>2024 Wiley‐VCH GmbH</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3737-e483669a8837e7804f57e1c8d019dcd38cd348eab84a3fa74e30795901f8f8ea3</citedby><cites>FETCH-LOGICAL-c3737-e483669a8837e7804f57e1c8d019dcd38cd348eab84a3fa74e30795901f8f8ea3</cites><orcidid>0000-0003-0985-0311 ; 0000-0002-5912-4871 ; 0000-0001-6986-5772 ; 0000-0003-1547-6880 ; 0000-0001-7671-2395 ; 0000-0002-3536-1485</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fadma.202308977$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fadma.202308977$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37968865$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zheng, Xiuli</creatorcontrib><creatorcontrib>Song, Xiaohai</creatorcontrib><creatorcontrib>Zhu, Guonian</creatorcontrib><creatorcontrib>Pan, Dayi</creatorcontrib><creatorcontrib>Li, Haonan</creatorcontrib><creatorcontrib>Hu, Jiankun</creatorcontrib><creatorcontrib>Xiao, Kai</creatorcontrib><creatorcontrib>Gong, Qiyong</creatorcontrib><creatorcontrib>Gu, Zhongwei</creatorcontrib><creatorcontrib>Luo, Kui</creatorcontrib><creatorcontrib>Li, Weimin</creatorcontrib><title>Nanomedicine Combats Drug Resistance in Lung Cancer</title><title>Advanced materials (Weinheim)</title><addtitle>Adv Mater</addtitle><description>Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy are currently available as treatment methods. However, drug resistance is a significant factor in the failure of lung cancer treatments. Novel therapeutics have been exploited to address complicated resistance mechanisms of lung cancer and the advancement of nanomedicine is extremely promising in terms of overcoming drug resistance. Nanomedicine equipped with multifunctional and tunable physiochemical properties in alignment with tumor genetic profiles can achieve precise, safe, and effective treatment while minimizing or eradicating drug resistance in cancer. Here, this work reviews the discovered resistance mechanisms for lung cancer chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy, and outlines novel strategies for the development of nanomedicine against drug resistance. This work focuses on engineering design, customized delivery, current challenges, and clinical translation of nanomedicine in the application of resistant lung cancer.
In this review, the discovered drug resistance mechanisms for lung cancer chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy are introduced. Recent advances of organic, inorganic, and bio‐derived nanomedicines for drug‐resistant lung cancer treatment are summarized. The engineering design, customized delivery, current challenges, and clinical translation of nanomedicine for lung cancer are discussed.</description><subject>Antineoplastic Agents - pharmacology</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Design engineering</subject><subject>Drug Delivery Systems</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>molecular targeted therapy</subject><subject>Nanomedicine</subject><subject>Neoplasms - drug therapy</subject><subject>Physiochemistry</subject><subject>Radiation therapy</subject><subject>radiotherapy</subject><issn>0935-9648</issn><issn>1521-4095</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LAzEQhoMotlavHmXBi5etk80mmRzL1i-oCqLnkO5my5b9qEkX6b83pbWCFw_DMMMzL8NDyCWFMQVIbk3RmHECCQNUUh6RIeUJjVNQ_JgMQTEeK5HigJx5vwQAJUCckgGTSiAKPiTsxbRdY4sqr1obZV0zN2sfTV2_iN6sr_zatLmNqjaa9e0iyraTOycnpam9vdj3Efm4v3vPHuPZ68NTNpnFOZNMxjZFJoQyiExaiZCWXFqaYwFUFXnBMFSK1swxNaw0MrUMpOIKaIll2LMRudnlrlz32Vu_1k3lc1vXprVd73WCCiTnTIqAXv9Bl13v2vCdThTlyLniNFDjHZW7zntnS71yVWPcRlPQW516q1MfdIaDq31sPw-SDviPvwCoHfBV1XbzT5yeTJ8nv-HfuHh-7w</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Zheng, Xiuli</creator><creator>Song, Xiaohai</creator><creator>Zhu, Guonian</creator><creator>Pan, Dayi</creator><creator>Li, Haonan</creator><creator>Hu, Jiankun</creator><creator>Xiao, Kai</creator><creator>Gong, Qiyong</creator><creator>Gu, Zhongwei</creator><creator>Luo, Kui</creator><creator>Li, Weimin</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>8BQ</scope><scope>8FD</scope><scope>JG9</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0985-0311</orcidid><orcidid>https://orcid.org/0000-0002-5912-4871</orcidid><orcidid>https://orcid.org/0000-0001-6986-5772</orcidid><orcidid>https://orcid.org/0000-0003-1547-6880</orcidid><orcidid>https://orcid.org/0000-0001-7671-2395</orcidid><orcidid>https://orcid.org/0000-0002-3536-1485</orcidid></search><sort><creationdate>20240101</creationdate><title>Nanomedicine Combats Drug Resistance in Lung Cancer</title><author>Zheng, Xiuli ; Song, Xiaohai ; Zhu, Guonian ; Pan, Dayi ; Li, Haonan ; Hu, Jiankun ; Xiao, Kai ; Gong, Qiyong ; Gu, Zhongwei ; Luo, Kui ; Li, Weimin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3737-e483669a8837e7804f57e1c8d019dcd38cd348eab84a3fa74e30795901f8f8ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antineoplastic Agents - pharmacology</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Design engineering</topic><topic>Drug Delivery Systems</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>molecular targeted therapy</topic><topic>Nanomedicine</topic><topic>Neoplasms - drug therapy</topic><topic>Physiochemistry</topic><topic>Radiation therapy</topic><topic>radiotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Xiuli</creatorcontrib><creatorcontrib>Song, Xiaohai</creatorcontrib><creatorcontrib>Zhu, Guonian</creatorcontrib><creatorcontrib>Pan, Dayi</creatorcontrib><creatorcontrib>Li, Haonan</creatorcontrib><creatorcontrib>Hu, Jiankun</creatorcontrib><creatorcontrib>Xiao, Kai</creatorcontrib><creatorcontrib>Gong, Qiyong</creatorcontrib><creatorcontrib>Gu, Zhongwei</creatorcontrib><creatorcontrib>Luo, Kui</creatorcontrib><creatorcontrib>Li, Weimin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><collection>MEDLINE - Academic</collection><jtitle>Advanced materials (Weinheim)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Xiuli</au><au>Song, Xiaohai</au><au>Zhu, Guonian</au><au>Pan, Dayi</au><au>Li, Haonan</au><au>Hu, Jiankun</au><au>Xiao, Kai</au><au>Gong, Qiyong</au><au>Gu, Zhongwei</au><au>Luo, Kui</au><au>Li, Weimin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanomedicine Combats Drug Resistance in Lung Cancer</atitle><jtitle>Advanced materials (Weinheim)</jtitle><addtitle>Adv Mater</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>36</volume><issue>3</issue><spage>e2308977</spage><epage>n/a</epage><pages>e2308977-n/a</pages><issn>0935-9648</issn><eissn>1521-4095</eissn><abstract>Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy are currently available as treatment methods. However, drug resistance is a significant factor in the failure of lung cancer treatments. Novel therapeutics have been exploited to address complicated resistance mechanisms of lung cancer and the advancement of nanomedicine is extremely promising in terms of overcoming drug resistance. Nanomedicine equipped with multifunctional and tunable physiochemical properties in alignment with tumor genetic profiles can achieve precise, safe, and effective treatment while minimizing or eradicating drug resistance in cancer. Here, this work reviews the discovered resistance mechanisms for lung cancer chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy, and outlines novel strategies for the development of nanomedicine against drug resistance. This work focuses on engineering design, customized delivery, current challenges, and clinical translation of nanomedicine in the application of resistant lung cancer.
In this review, the discovered drug resistance mechanisms for lung cancer chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy are introduced. Recent advances of organic, inorganic, and bio‐derived nanomedicines for drug‐resistant lung cancer treatment are summarized. The engineering design, customized delivery, current challenges, and clinical translation of nanomedicine for lung cancer are discussed.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37968865</pmid><doi>10.1002/adma.202308977</doi><tpages>48</tpages><orcidid>https://orcid.org/0000-0003-0985-0311</orcidid><orcidid>https://orcid.org/0000-0002-5912-4871</orcidid><orcidid>https://orcid.org/0000-0001-6986-5772</orcidid><orcidid>https://orcid.org/0000-0003-1547-6880</orcidid><orcidid>https://orcid.org/0000-0001-7671-2395</orcidid><orcidid>https://orcid.org/0000-0002-3536-1485</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0935-9648 |
| ispartof | Advanced materials (Weinheim), 2024-01, Vol.36 (3), p.e2308977-n/a |
| issn | 0935-9648 1521-4095 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2890755376 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antineoplastic Agents - pharmacology Cancer therapies Chemotherapy Design engineering Drug Delivery Systems Drug resistance Drug Resistance, Neoplasm Humans Immunotherapy Lung cancer Lung Neoplasms - drug therapy molecular targeted therapy Nanomedicine Neoplasms - drug therapy Physiochemistry Radiation therapy radiotherapy |
| title | Nanomedicine Combats Drug Resistance in Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T02%3A35%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanomedicine%20Combats%20Drug%20Resistance%20in%20Lung%20Cancer&rft.jtitle=Advanced%20materials%20(Weinheim)&rft.au=Zheng,%20Xiuli&rft.date=2024-01-01&rft.volume=36&rft.issue=3&rft.spage=e2308977&rft.epage=n/a&rft.pages=e2308977-n/a&rft.issn=0935-9648&rft.eissn=1521-4095&rft_id=info:doi/10.1002/adma.202308977&rft_dat=%3Cproquest_cross%3E2890755376%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2915855951&rft_id=info:pmid/37968865&rfr_iscdi=true |